Five pharma companies found guilty of UK's PMCPA code breaches

13 December 2016

The UK regulator has ruled on breaches of the Association of British Pharmaceutical Industry (ABPI) code of conduct by five separate pharma companies.

In advertisements to appear in Nursing standards, the Pharmaceutical Journal and British Medical Journal this month, the Prescriptions Medicines Code of Practice Authority (PMCPA) named German privately-owned drugmakers Grünenthal and Boehringer Ingelheim, along with US pharma major Eli Lilly (NYSE: LLY) and the UK's AstraZeneca (LSE: AZN), as well US healthcare giant Johnson & Johnson (NYSE: JNJ) unit Janssen-Cilag, as the companies to have breached the code of practice for the UK pharmaceutical industry.

The code covers the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK